Nonalcoholic steatohepatitis (
NASH) is a hepatic disorder associated with the metabolic syndrome
and insulin resistance. It is a very common problem for which no therapy, short of diet/weight loss and exercise, has shown benefit. Extreme measures of weight loss include bariatric surgery, which has not been well studied, but may be beneficial.[1] Accordingly, there is considerable interest in developing pharmacologic therapies directed toward addressing the presence of insulin resistance.